Exact Sciences

In a separate study, researchers studying the use of Oncotype DX in African-American men found it to be predictive of disease outcomes regardless of race.

New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.

The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.

Exact Sciences and the Mayo Clinic are working to develop a blood test for pancreatic cancer that might be able to diagnose patients with early-stage disease.

During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.

The firm recently submitted an application to the US Food and Drug Administration to expand Cologuard's label to the 45 to 49 age group.